ESG401

ESG401 is an investigational agent whose form is not stated in the registry developed by Qilu Pharmaceutical. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT06732323 (A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer) and NCT06383767 (A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer), in triple-negative breast cancer and HR-positive / HER2-negative breast cancer. The largest, NCT06732323, plans to enrol 504 participants with primary completion expected 2027-06. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.